Tag:
GlobeImmune
Latest Headlines
Latest Headlines
Gilead, GlobeImmune team up on HBV vaccines
Gilead Sciences ( $GILD ) is giving GlobeImmune an undisclosed upfront payment for early development and funding to support continued development of its hepatitis B virus (HBV) therapeutic vaccine
Two GlobeImmune cancer vaccines well tolerated
Good news for GlobeImmune and its Tarmogen vaccine platform: the company released positive safety and immunogenicity data for GI-4000 and GI-6207, which treat lung adenocarcinoma and carcinoembryonic
GlobeImmune HCV vax shows promise in trial
GlobeImmune's GI-5005, the company's investigational Tarmogen product, improved sustained virologic response by 12 percent in patients with genotype 1 chronic hepatitis C virus infection who had
GlobeImmune cuts 25% of staff
Roughly six months after raising $17.5 million for Phase III work, Louisville, CO-based GlobeImmune says it has laid of 15 of its 60 employees--or 25 percent. "Basically we were adjusting the
GlobeImmune raises $17.5M as it heads toward Phase III
Louisville, CO-based GlobeImmune has hauled in a $17.5 million Series E round, which was led by Generali Financial Holding and BSI SA. This past year was a "difficult" one for the entire industry,
Celgene, GlobeImmune ink $500M deal
GlobeImmune will receive $40 million up front in a deal with Celgene that could be worth up to $500 million. The two companies have entered into a worldwide strategic collaboration for the discovery,
Tibotec reveals TMC435 data
Tibotec has announced new interim clinical data showing antiviral activity of TMC435, an investigational protease inhibitor for chronic hepatitis C virus infection. In interim findings from the first
Emerging Drug Developer: GlobeImmune
Emerging Drug Developer: GlobeImmune Platform companies that can show promise against a number of diseases have been flourishing,
GlobeImmune lands $41M venture round
With its lead drug in Phase II for pancreatic cancer and a hepatitis C drug slated to forge into a mid-stage study later this year, GlobeImmune has rounded up $41.2 million in its third round of
